Singapore, May 13 -- US-based BostonGene, developer of the leading AI foundation model for tumour and immune biology, has announced the expanded strategic research collaboration with Japan's Hokkaido University.

This multi-year initiative is designed to produce actionable, high-quality, clinically relevant data that support the development of precision therapies and ultimately improve outcomes for cancer patients in Japan.

Published by HT Digital Content Services with permission from BioSpectrum Asia....